A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients

BackgroundMetabolic-associated fatty liver disease (MAFLD) is becoming increasingly prevalent in non-obese patients with type 2 diabetes mellitus (T2DM) and leads to serious liver damage in this population. The study aims to develop and validate a nomogram to predict the risk of MAFLD in non-overwei...

Full description

Saved in:
Bibliographic Details
Main Authors: Yuliang Cui, Fenghua Li, Tingting Li, Wanjing Sun, Haiyan Shi, Yunyun Cheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1521168/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849687487911297024
author Yuliang Cui
Fenghua Li
Tingting Li
Wanjing Sun
Haiyan Shi
Yunyun Cheng
author_facet Yuliang Cui
Fenghua Li
Tingting Li
Wanjing Sun
Haiyan Shi
Yunyun Cheng
author_sort Yuliang Cui
collection DOAJ
description BackgroundMetabolic-associated fatty liver disease (MAFLD) is becoming increasingly prevalent in non-obese patients with type 2 diabetes mellitus (T2DM) and leads to serious liver damage in this population. The study aims to develop and validate a nomogram to predict the risk of MAFLD in non-overweight individuals with newly diagnosed T2DM.MethodsA total of 2372 non-obese patients with newly diagnosed T2DM and MAFLD were enrolled and randomly assigned to the training and validation sets in a ratio of 7:3. The independent risk factors associated with MAFLD were screened by univariate and multivariate logistic regression, and a nomogram was constructed to predict the risk of MAFLD. Receiver operating characteristic curve (ROC), calibration curves, and decision curve analysis (DCA) were used to verify the performance and clinical utility of the model.ResultsSeven predictors, namely body mass index (BMI), alanine aminotransferase/aspartate aminotransferase (ALT/AST), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), fasting blood glucose (FBG), creatinine (Cr) and serum uric acid (SUA), were identified by multivariate logistic regression analysis from a total of 14 variables studied. The nomogram built using these seven predictors showed good prediction ability (AUC: 0.815 in the training cohort; AUC: 0.787 in the validation cohort), along with favorable calibration and clinical utility.ConclusionThe nomogram demonstrated effectiveness as a screening tool for evaluating the risk of MAFLD in T2DM individuals without obesity, facilitating early identification and supporting enhanced management strategies for MAFLD.
format Article
id doaj-art-c1686430d9d14e45aae559e6bee18995
institution DOAJ
issn 1664-2392
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-c1686430d9d14e45aae559e6bee189952025-08-20T03:22:19ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-05-011610.3389/fendo.2025.15211681521168A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patientsYuliang Cui0Fenghua Li1Tingting Li2Wanjing Sun3Haiyan Shi4Yunyun Cheng5Department of Endocrinology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, ChinaDepartment of Endocrinology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, ChinaDepartment of Endocrinology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, ChinaDepartment of Pharmacy, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, ChinaDepartment of Endocrinology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, ChinaDepartment of Pharmacy, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, ChinaBackgroundMetabolic-associated fatty liver disease (MAFLD) is becoming increasingly prevalent in non-obese patients with type 2 diabetes mellitus (T2DM) and leads to serious liver damage in this population. The study aims to develop and validate a nomogram to predict the risk of MAFLD in non-overweight individuals with newly diagnosed T2DM.MethodsA total of 2372 non-obese patients with newly diagnosed T2DM and MAFLD were enrolled and randomly assigned to the training and validation sets in a ratio of 7:3. The independent risk factors associated with MAFLD were screened by univariate and multivariate logistic regression, and a nomogram was constructed to predict the risk of MAFLD. Receiver operating characteristic curve (ROC), calibration curves, and decision curve analysis (DCA) were used to verify the performance and clinical utility of the model.ResultsSeven predictors, namely body mass index (BMI), alanine aminotransferase/aspartate aminotransferase (ALT/AST), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-C), fasting blood glucose (FBG), creatinine (Cr) and serum uric acid (SUA), were identified by multivariate logistic regression analysis from a total of 14 variables studied. The nomogram built using these seven predictors showed good prediction ability (AUC: 0.815 in the training cohort; AUC: 0.787 in the validation cohort), along with favorable calibration and clinical utility.ConclusionThe nomogram demonstrated effectiveness as a screening tool for evaluating the risk of MAFLD in T2DM individuals without obesity, facilitating early identification and supporting enhanced management strategies for MAFLD.https://www.frontiersin.org/articles/10.3389/fendo.2025.1521168/fullmetabolic-associated fatty liver diseasetype 2 diabetes mellituswithout obesitynomogramrisk prediction
spellingShingle Yuliang Cui
Fenghua Li
Tingting Li
Wanjing Sun
Haiyan Shi
Yunyun Cheng
A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients
Frontiers in Endocrinology
metabolic-associated fatty liver disease
type 2 diabetes mellitus
without obesity
nomogram
risk prediction
title A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients
title_full A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients
title_fullStr A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients
title_full_unstemmed A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients
title_short A nomogram for predicting metabolic-associated fatty liver disease in non-obese newly diagnosed type 2 diabetes patients
title_sort nomogram for predicting metabolic associated fatty liver disease in non obese newly diagnosed type 2 diabetes patients
topic metabolic-associated fatty liver disease
type 2 diabetes mellitus
without obesity
nomogram
risk prediction
url https://www.frontiersin.org/articles/10.3389/fendo.2025.1521168/full
work_keys_str_mv AT yuliangcui anomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT fenghuali anomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT tingtingli anomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT wanjingsun anomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT haiyanshi anomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT yunyuncheng anomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT yuliangcui nomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT fenghuali nomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT tingtingli nomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT wanjingsun nomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT haiyanshi nomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients
AT yunyuncheng nomogramforpredictingmetabolicassociatedfattyliverdiseaseinnonobesenewlydiagnosedtype2diabetespatients